What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria?

Bone Marrow Transplantation

Volumn 38, Issue 3, 2006, Pages 183-188

  Kelly, M ^a   Roy, D C ^a   Labbe, A C ^a   Laverdiere, M ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; COTRIMOXAZOLE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM CONTAMINATION; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FEVER; FOLLOW UP; GRAFT RECIPIENT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS EPIDERMIDIS; UNSPECIFIED SIDE EFFECT;

ADULT; BACTEREMIA; CHI-SQUARE DISTRIBUTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746575156     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705421     Document Type: Article

References (19)

1. Foundation for the Accreditation of Hematopoietic Cell Therapy. Standards for Hematopoietic Progenitor Cell Collection, Processing, and Transplantation. 1st edn. Omaha, Neb 1996; Ch.FAHCT Accreditation Office.
2. Progenitor Cell Standards Task Force. Standards for Hematopoietic Progenitor Cell Services. 2nd edition [American Association of Blood Banks]. Bethesda, MD, 2000, pp 22-58.
3. Nasser RM, Hajjar I, Sandhaus LM, Hall GS, Avery RK, Bolwell BJ et al. Routine cultures of bone marrow and peripheral stem cell harvests: clinical impact, cost analysis, and review. Clin Infect Dis 1998; 27: 886-888.
4. Webb IJ, Coral FS, Andersen JW, Elias AD, Finberg RW, Nadler LM et al. Sources and sequelae of bacterial contamination of hematopoietic stem cell components: Implications for the safety of hematotherapy and graft engineering. Transfusion 1996; 36: 782-788.
5. Prince HM, Page SR, Keating A, Saragosa RF, Vukovic NM, Imrie KR et al. Microbial contamination of harvested bone marrow and peripheral blood. Bone Marrow Transplant 1995; 15: 87-91.
6. Rowley SD, Davis J, Dick J, Braine HG, Charache P, Saral R et al. Bacterial contamination of bone marrow grafts intended for autologous and allogeneic bone marrow transplantation. Incidence and clinical significance. Transfusion 1988; 28: 109-112.
7. Lazarus HM, Magalhaes-Silverman M, Fox RM, Creger RJ, Jacobs M. Contamination during in vitro processing of bone marrow for transplantation: Clinical significance. Bone Marrow Transplant 1991; 7: 241-246.
8. Nifong TP, Ehmann WC, Mierski JA, Domen RE, Rybka WB. Favorable outcome after infusion of coagulase-negative staphylococci-contaminated peripheral blood hematopoietic cells for autologous transplantation. Arch Pathol Lab Med 2003; 127: E19-e21.
9. Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J. Anti-MY9-blocked-ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 1991; 77: 2404-2412.
10. Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA et al. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol 1995; 15: 51-57.
11. Roy DC, Dallaire N, Moreau B, Paquette Y, Balassy A, Giorgi O et al. Photodynamic therapy of B-lineage non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 2000; 96: 793a.
12. Roy DC, Boileau J, Laplante J, Busque L, Fish D, Kassis J et al. Phase I study of autologous progenitor cell transplantation purged with a photodynamic approach for patients with chronic myeloid leukemia. Blood 2000; 96: 583a.
13. Roy DC. Purging of leukemia cells with a photodynamic approach. Leuk Lymphoma 1998; 30: 50.
14. Andre-Schmutz I, Le DF, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: A phase 1/2 study. Lancet 2002; 360: 130-137.
15. Dal-Cortivo L, Ouachee-Chardin M, Hirsch I, Blanche S, Fischer A, Cavazzana-Calvo M et al. Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity? Bone Marrow Transplant 2004; 34: 945-947.
16. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC. P-glycoprotein targeting: A unique strategy to selectively eliminate immunoreactive T cells. Blood 2002; 100: 375-382.
17. Sidi Boumedine R, Roy DC. Elimination of alloreactive T cells using photodynamic therapy. Cytotherapy 2005; 7: 134-143.
18. York MK, Thomson RB. Body fluid cultures (excluding blood, cerebrospinal fluid and urine). In: Isenberg HD (ed). Clinical Microbiology Procedures Handbook, chapter 3.5.1, 2nd edn. ASM Press: Cleveland, OH, 2004.
19. Khuu HM, Cowley H, David-Ocampo V, Carter CS, Kasten-Sportes C, Wayne AS et al. Catastrophic failures of freezing bags for cellular therapy products: Description, cause, and consequences. Cytotherapy 2002; 4: 539-549.